Xtl Biopharmaceuticals (XTLB) Non Operating Income (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Non Operating Income of $427000.0 for Q4 2024, up 608.33% year-on-year from $60282.4 in Q1 2024, and up 102.37% on a QoQ basis from $211000.0 in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Non Operating Income (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Non Operating Income for 16 consecutive years, with $427000.0 the latest figure, recorded in Q4 2024.
- Quarterly Non Operating Income rose 608.33% year-over-year to $427000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1.0 million (up 199.8% YoY) and the FY2025 annual result came in at $929000.0, down 8.47% from the prior year.
- Non Operating Income rose to $427000.0 in Q4 2024 per XTLB's latest filing, from $211000.0 in the prior quarter.
- Over the last five years, Non Operating Income for XTLB reached as high as $1.6 million in Q3 2020 and fell as low as -$3.2 million in Q4 2020.
- A 5-year average of -$50450.0 and a median of -$73500.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2020 — Non Operating Income sank 1032.27% — and 2024, when it jumped 608.33%.
- Year by year, Non Operating Income stood at -$3.2 million in 2020, then surged by 117.26% to $551000.0 in 2021, then tumbled by 194.92% to -$523000.0 in 2022, then jumped by 83.94% to -$84000.0 in 2023, then soared by 608.33% to $427000.0 in 2024.
- According to Business Quant data, Non Operating Income over the past three periods registered $427000.0, $211000.0, and -$283000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Xtl Biopharmaceuticals | 2.60 Bn | 2.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 427,000.00 |
| Sep 30, 2024 | 211,000.00 |
| Jun 30, 2024 | -283,000.00 |
| Mar 31, 2024 | 660,000.00 |
| Dec 31, 2023 | -84,000.00 |
| Sep 30, 2023 | -64,000.00 |
| Jun 30, 2023 | -201,000.00 |
| Mar 31, 2023 | -668,000.00 |
| Dec 31, 2022 | -523,000.00 |
| Sep 30, 2022 | -617,000.00 |
| Jun 30, 2022 | -83,000.00 |
| Mar 31, 2022 | 755,000.00 |
| Dec 31, 2021 | 551,000.00 |
| Sep 30, 2021 | 1.25 Mn |
| Jun 30, 2021 | -847,000.00 |
| Mar 31, 2021 | 518,000.00 |
| Dec 31, 2020 | -3.19 Mn |
| Sep 30, 2020 | 1.65 Mn |
| Jun 30, 2020 | -888,000.00 |
| Mar 31, 2020 | 430,000.00 |